Somatrogon-ghla

(Ngenla®)

Ngenla®

Latest News

loading GIF

Drug updated on 4/16/2024

Dosage FormInjection (subcutaneous; 24 mg/1.2 mL [20 mg/mL] single-patient-use prefilled pen that delivers a dose in 0.2 mg increments, 60 mg/1.2 mL [50 mg/mL] single-patient-use prefilled pen that delivers a dose in 0.5 mg increments)
Drug ClassHuman growth hormone analogs
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of pediatric patients aged 3 years and older who have growth failure due to inadequate secretion of endogenous growth hormone

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Somatrogon-ghla (Ngenla) is indicated for the treatment of pediatric patients aged 3 years and older who have growth failure due to inadequate secretion of endogenous growth hormone.
  • One systematic review/meta-analysis was reviewed, which compared Ngenla with other long-acting growth hormone preparations and daily treatments in children with Growth Hormone Deficiency (GHD).
  • The efficacy comparison showed no significant difference between Ngenla and conventional daily Growth Hormone therapies in terms of height velocity outcomes.
  • In terms of safety, adherence, quality of life indicators, all Long Acting Growth Hormones including Ngenla were found similar to daily GH based on the studies reviewed.
  • The study specifically targeted children with GHD but did not delineate findings across different subgroups within this population such as age brackets or severity levels.
  • The review acknowledged limitations like risk bias across included studies and the absence of real-world data addressing long-term adherence & Quality Of Life; it called for future high-quality research emphasizing the economic impact from a healthcare payer perspective.